CymaBay Therapeutics Inc. (NASDAQ:CBAY) SVP Charles Mcwherter purchased 5,000 shares of CymaBay Therapeutics stock in a transaction dated Thursday, July 20th. The shares were bought at an average price of $7.43 per share, with a total value of $37,150.00. Following the completion of the acquisition, the senior vice president now directly owns 5,100 shares of the company’s stock, valued at $37,893. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded up 0.32% during midday trading on Friday, reaching $6.26. The company had a trading volume of 946,917 shares. The firm has a 50-day moving average of $6.64 and a 200 day moving average of $4.54. CymaBay Therapeutics Inc. has a 1-year low of $1.15 and a 1-year high of $8.29. The company’s market capitalization is $273.91 million.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. On average, equities research analysts forecast that CymaBay Therapeutics Inc. will post ($0.77) EPS for the current year.
WARNING: This news story was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/20/cymabay-therapeutics-inc-cbay-svp-charles-mcwherter-purchases-5000-shares-updated-updated-updated.html.
Several equities analysts have recently weighed in on CBAY shares. Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a report on Monday, July 17th. Citigroup Inc. restated an “outperform” rating and set a $15.00 price target (up from $8.00) on shares of CymaBay Therapeutics in a report on Thursday, July 20th. Oppenheimer Holdings, Inc. lifted their price objective on CymaBay Therapeutics from $8.00 to $15.00 and gave the stock an “outperform” rating in a report on Thursday, July 20th. ValuEngine upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, CIBC reiterated an “outperform” rating and issued a $15.00 price objective (up from $8.00) on shares of CymaBay Therapeutics in a report on Thursday, July 20th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. CymaBay Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.32.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. TFS Capital LLC purchased a new position in shares of CymaBay Therapeutics during the first quarter worth $169,000. Boxer Capital LLC purchased a new position in shares of CymaBay Therapeutics during the first quarter worth $3,342,000. ClariVest Asset Management LLC purchased a new position in shares of CymaBay Therapeutics during the first quarter worth $105,000. Acadian Asset Management LLC purchased a new position in shares of CymaBay Therapeutics during the first quarter worth $129,000. Finally, LVM Capital Management Ltd. MI raised its position in shares of CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 10,000 shares in the last quarter. 25.39% of the stock is currently owned by institutional investors and hedge funds.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.